LEVY ANDREW has a total of 22 patent applications. Its first patent ever was published in 1909. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and United Kingdom. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are BORLAK JUERGEN, HUBIT GENOMIX INC and ORIDIS BIOMED FORSCHUNGS UND E.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 14 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | United Kingdom | 3 | |
#4 | EPO (European Patent Office) | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Medical technology | |
#5 | Foods and drinks | |
#6 | Furniture and games | |
#7 | Agriculture |
# | Technology | |
---|---|---|
#1 | Analysing materials | |
#2 | Measuring microorganism processes | |
#3 | Therapeutic chemical compounds | |
#4 | Medical preparations | |
#5 | Syringes | |
#6 | Peptides | |
#7 | Enzymes | |
#8 | Diagnosis and surgery | |
#9 | Physical training equipment | |
#10 | Animal care |
# | Name | Total Patents |
---|---|---|
#1 | Levy Andrew | 22 |
#2 | Levy Nina | 4 |
#3 | Berkowitz Noah | 3 |
Publication | Filing date | Title |
---|---|---|
GB201017792D0 | Tube anchor assembly | |
WO2010018383A1 | Device for detecting skin sensitivity and use of the same | |
US2009246770A1 | Glycemic control for reduction of cardiovascular disease risk in diabetic patients expressing haptoglobin 2-2 | |
US2008213785A1 | Method of predicting a benefit of antioxidant therapy for prevention or treatment of vasclar disease in hyperglycemic individuals | |
US2008044399A1 | Vitamin E supplementation for reducing cardiovascular events in individuals with DM and the Hp 2-2 genotype | |
US2007014764A1 | Reduction in myocardial infarction size | |
GB191013444A | Apparatus for Marking or Stamping Golf and like Balls. | |
GB190920076A | Apparatus for Marking or Stamping Golf and like Balls. |